Tyzivumab - Tychan/WuXi Biologics

Drug Profile

Tyzivumab - Tychan/WuXi Biologics

Alternative Names: TY008

Latest Information Update: 05 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tychan
  • Developer Tychan; WuXi Biologics
  • Class Antivirals; Monoclonal antibodies; Small molecules
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Zika virus infection

Most Recent Events

  • 08 Feb 2018 Phase-I clinical trials in Zika virus infection in Singapore (IV) (NCT03443830)
  • 07 Feb 2018 Tychan and WuXi Biologics collaborate to co-develop Tyzivumab for Zika virus infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top